EVKEEZA

This brand name is authorized in Estonia, France, Croatia, Ireland, Italy, Lithuania, Poland, United Kingdom, United States

Active ingredients

The drug EVKEEZA contains one active pharmaceutical ingredient (API):

1 Evinacumab UNII T8B2ORP1DW - EVINACUMAB

Evinacumab is a recombinant human monoclonal antibody, which specifically binds to and inhibits ANGPTL3. ANGPTL3 is a member of the angiopoietin-like protein family that is expressed primarily in the liver and plays a role in the regulation of lipid metabolism by inhibiting lipoprotein lipase (LPL) and endothelial lipase (EL). Evinacumab blockade of ANGPTL3 lowers TG and HDL-C by releasing LPL and EL activities from ANGPTL3 inhibition, respectively. Read about Evinacumab

Medication package inserts

Below package inserts are available for further reading:

Title	Information Source	Document Type
EVKEEZA Concentrate for solution for infusion	European Medicines Agency (EU)	MPI, EU: SmPC

Medicine classification

This drug has been classified in the anatomical therapeutic chemical (ATC) classification system as follows:

ATC code	Group title	Classification
C10AX	Other lipid modifying agents	C Cardiovascular system → C10 Lipid modifying agents → C10A Lipid modifying agents, plain
Discover more medicines within C10AX

Authorization and marketing

This drug has been assigned below unique identifiers within the countries it is being marketed:

Country	Identification scheme	Identifier(s)
Country: EE	Ravimiamet	Identifier(s): 1852545, 1852556
Country: FR	Base de données publique des médicaments	Identifier(s): 64336907
Country: IT	Agenzia del Farmaco	Identifier(s): 049619012, 049619024
Country: LT	Valstybinė vaistų kontrolės tarnyba	Identifier(s): 1092848, 1092849
Country: PL	Rejestru Produktów Leczniczych	Identifier(s): 100455264
Country: US	FDA, National Drug Code	Identifier(s): 61755-010, 61755-013